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MTT Assay
1. Serial dilute 50 mM stock solution of MQ with DMSO. Seed NB4 and U937 with 
RPMI media (10% FBS, 1% PS) at 2 x 105 cells/mL and 1 x 105 cells/mL, 
respectively. Total volume per well: 100 µL.
2. Incubate plates for 48 hours. Add 10 µL of MTT reagent, incubate for 4 hours, then 
add 100 µL of detergent. 
3. Store in the dark for 24 hours. Record absorbance at 595 nm and determine IC50.
Trypan Blue Staining
1. Perform similar pre-incubation steps as the MTT protocol
2. After 48 hours, perform a cell count with Trypan Blue to view cell viability at 
increasing MQ concentrations (include IC50s: 7 µM for NB4 and 8 µM for U937)
Western Blot
1. Prepare lysates of NB4 and U937 cells with MQ treatment for 0,  2, 4, and 24h. 
Run gel electrophoresis.
2. Perform electrotransfer of the proteins using polyvinylidene fluoride (PDVF) 
membrane 
3. Wash membrane in Ponceau S staining solution. Block membrane in 10% milk 
(with TBST) to rid of background “noise.” 
4. Wash in 5% milk with the primary antibody (1:1000) overnight in 4oC shaker. 
Wash membrane three times in TBST for 10 min. 
5. Wash in 5% milk with secondary antibody (1:3000) for 1 hour. Wash membrane 
three times in TBST for 10 min.
6. Prepare ECL mix (1:2 dilution of solution A and B).
7. Visualize results in dark room for chemiluminescent detection.
MTT Dose Response Results (48h)
Trypan Blue Results (48h)
Statistical Comparisons:
Fig. 2 - Standard deviations (SD) and standard error of means (SEM) displayed in the table served as separate 
comparisons between the MTT and trypan blue assay trials from the graphs. The two-tailed p-value in paired t-tests 
were then computed to see the statistical significance between MTT and trypan blue; p-values were less than 0.05 
for both NB4 and U937.
BACKGROUND
Acute leukemia is a fast-growing blood cancer with an early onset in 
hematopoietic stem cells. DNA mutations block normal development in lymphoid and 
myeloid cells, leading to an accumulation of blast cells in the bone marrow. This can 
result in either acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) 
as shown in Fig. 1. With 2-year survival rates of less than 20% in the elderly and 60% 
in children [2], AML became the main focus for this project.
The growth maintenance of cancer cells depend partially on autophagy, a catabolic 
process that degrades and recycles unwanted proteins and organelles in the lysosome 
for cell survival. Based on previous studies, leukemic cells undergoing autophagy 
inhibition experience metabolic stress, triggering apoptosis [3]. 
The use of an antimalarial drug, mefloquine (MQ), has sparked interest in drug 
repurposing for leukemic cells due to its effective reduction of parasitemia from blood. 
Mefloquine’s current mechanism of action for malaria includes damaging the 
membrane of free heme, interacting with phosphatidylinositol, and affecting volume-
regulated anion channels (VRAC) to bring toxicity to parasites in blood [5]. A high-
throughput screening panel of leukemic cell lines identified mefloquine as an anti-
leukemic compound by lysosome disruption, releasing cathepsins into the cytosol and 
causing permeability in the lysosome membrane [2].
HYPOTHESIS
 The repurposing of mefloquine (MQ) as an anti-leukemic drug will result in 
decreased myeloid leukemia cell proliferation due to lysosome disruption, thereby 
inhibiting autophagy and inducing apoptosis. 
METHODS
We found that AML cells, NB4 and U937, had mean IC50 values respectively at 7µM and 8µM mefloquine 
(MQ) treatment through verification in MTT and trypan blue assays. The MTT assay uses tetrazolium dye 
reduction to measure metabolism as a marker for cell proliferation. Cells with increasing MQ concentration had 
the least metabolism by losing their ability to convert the MTT into formazan and revealing less color as 
quantified by absorbance. The trypan blue assay was used to evaluate anti-proliferative effects based on cell 
viability. The mean IC50 values between the MTT and trypan blue assays were statistically insignificant because 
p > 0.05 for both cell lines (Fig. 2). Having little difference in procedural methods, 7µM for NB4 and 8µM for 
U937 were used for future experiments. Western blotting was performed to detect protein expression using 
apoptosis and autophagy markers. These cells were treated at 0, 2, 4, and 24 hours of MQ treatment to investigate 
molecular processes before 48 hours. 
Apoptosis Markers
The p53 tumor suppressor gene induces apoptosis by protease enzymes in the Caspase family. Cleaved 
Caspase-3 is needed in order to activate the proteolytic cleavage of PARP for the induction of apoptosis [4]. Since 
there was no Caspase-3 cleavage in the results, there was no induction of apoptosis for NB4 and U937 with MQ. 
PARP-1 repairs single-stranded DNA (ssDNA) breaks, helping to maintain cell viability. Unlike Caspase-3, there 
was an indication of PARP-1 cleavage, which allows for the likelihood of autophagy inhibition instead if 
cathepsins proteases are involved in autophagosomes [4]. Elevated levels of CHOP initiate apoptosis through ER 
stress. Since CHOP levels were inconsistent in the results, apoptosis may not have occurred. (Fig. 3)
Autophagy Markers
Atg-5 and Atg-7 are important molecules for the induction of autophagy through the formation of 
autophagosomes [1]. Although only Atg-5 was cleaved, it served as an indicator of apoptosis. A different pathway 
may be involved since there was no cleavage of Atg-7. Due to the inclusion of p62 in signal transduction 
pathways and degradation of ubiquitinated proteins, having no p62 cleavage in the cell lines implies that 
autophagy was not inhibited in this pathway [4]. LC3, a marker of autophagosomes, is the main protein in the 
autophagy pathway. A higher protein expression in LC3B-II means increased chances for autophagy [4], so based 
on the results, LC3 lipidation is not a contributor to autophagy inhibition. (Fig. 3)
CONCLUSIONS
 Although IC50 values were obtained for NB4 and U937 cells, there was little evidence that mefloquine (MQ) 
inhibited autophagy or induced apoptosis. A distinct DMSO control for Western blots, longer time points, IC90 
trials, other cell lines, and different assays such as flow cytometry will have to be included to evaluate the drug 
repurposing of mefloquine. Additional anticancer drugs will also be tested. We hope that our results will 
eventually provide the rationale to continue with clinical trials.
RESULTS
RESULTS (cont.)
Western Blot Results
Fig. 3 - Apoptosis Markers: PARP-1, Caspase-3, CHOP; Autophagy Markers: Atg-7, Atg-5, p62, LC3B 
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Cell Line Trypan Blue Mean IC50 (48h)
NB4 7 µM
U937 9.5 µM
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NB4 6.9 µM (~ 7 µM)
U937 8.2 µM (~ 8 µM)
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NB4: MTT vs. Trypan Blue IC50 Values (48h)
U937: MTT vs. Trypan Blue IC50 Values (48h)
The aim of this study is to observe cell proliferation, cell viability, apoptosis, and 
autophagy on acute myeloid leukemia (AML) cell lines, NB4 and U937, with the drug 
repurposing of mefloquine (MQ). Methods such as the 3-(4,5-Dimethylthiazol-2-Yl)-
2,5-Diphenyltetrazolium Bromide (MTT) assay and trypan blue staining have shown a 
decrease in live cells with high concentrations of mefloquine. Using their average 
perspective IC50 values of MQ concentration, Western blotting was applied by means 
of apoptosis and autophagy markers to determine if the induction of apoptosis and 
inhibition of autophagy was present in MQ-treated AML cells. The experiment will be 
continued with more cell lines, drugs, and other means of protocol in order to 
contribute to cancer therapy.
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Fig. 1 - Hematopoiesis for Acute Leukemia
